Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

INCLIVA, Biomedical Research Institute

1 abstract

Abstract
Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort.
Org: Affimed Inc., Samsung Medical Center, INCLIVA, Biomedical Research Institute, Vall d'Hebron Institute of Oncology, Affimed,